SavedAdd your journal

Journals / Anatolian Current Medical Journal / 2026 / Volume: 8 Issue: 4

Pan-immune inflammatory value predicts atrial fibrillation recurrence after direct current cardioversion

Şükriye Uslu(Health Science University, Antalya Training and Research Hospital, Department of Cardiology)0000-0001-7504-7637
Görkem Kuş(Health Science University, Antalya Training and Research Hospital, Department of Cardiology)0000-0002-6058-5501
Gülsüm Meral Yılmaz Öztekin(Health Science University, Antalya Training and Research Hospital, Department of Cardiology)0000-0001-9540-5075
Göksel Çağırcı(Health Science University, Antalya Training and Research Hospital, Department of Cardiology)0000-0001-9768-918X
Şakir Arslan(Health Science University, Antalya Training and Research Hospital, Department of Cardiology)0000-0002-2907-4957
Pages
—
Publication Date
2026-07-16
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest its potential use in clinical practice for risk stratification of patients undergoing DCCV, enabling more personalized post-cardioversion management strategies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: We aimed to determine whether there is a relationship between the pan-immune inflammatory value (PIV) and the recurrence of atrial fibrillation (AF) after successful direct current cardioversion (DCCV).
📊
Key Findings & Data:Methods: The study included 113 patients with persistent AF who underwent successful DCCV between 2015 and 2023.
💡
Conclusion & Impact:These findings suggest its potential use in clinical practice for risk stratification of patients undergoing DCCV, enabling more personalized post-cardioversion management strategies.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Atrial fibrillation · electrical cardioversion · recurrence

Abstract

Aims: We aimed to determine whether there is a relationship between the pan-immune inflammatory value (PIV) and the recurrence of atrial fibrillation (AF) after successful direct current cardioversion (DCCV). Methods: The study included 113 patients with persistent AF who underwent successful DCCV between 2015 and 2023. Results: During the 12-month follow-up, AF recurrence was observed in 38 patients (33.6%). Median PIV was significantly higher in patients who developed recurrence than in those who maintained sinus rhythm (SR) (416.1 vs. 277.0; p=0.0012). The optimal PIV cut-off value was 318.6, providing 76.3% sensitivity and 36.5% specificity. Cox regression analysis identified PIV (HR 1.736, p=0.0260) and coronary artery disease (CAD) (HR 2.276, p=0.0332) as independent predictors of AF recurrence. Conclusion: As a simple and cost-effective biomarker, PIV is an independent predictor of recurrence after DCCV in patients with persistent AF. These findings suggest its potential use in clinical practice for risk stratification of patients undergoing DCCV, enabling more personalized post-cardioversion management strategies.

🔖

Cite This Article

Uslu, Ş., Kuş, G., Öztekin, G. M. Y., Çağırcı, G., Arslan, Ş. (2026). Pan-immune inflammatory value predicts atrial fibrillation recurrence after direct current cardioversion. Anatolian Current Medical Journal, Volume: 8 Issue: 4. https://doi.org/10.38053/acmj.1954850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217-221. doi:10.1177/1747493019897870
  2. Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161-1169. doi:10.1016/S0140-6736(16)30968-0
  3. Menyhart O, Fekete JT, Gyorffy B. Inflammation and colorectal cancer: a meta-analysis of the prognostic significance of the Systemic Immune-inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI). Int J Mol Sci. 2024;25(15):8441. doi:10.3390/ijms25158441
  4. Ye Z, Hu T, Wang J, et al. Systemic Immune-inflammation Index as a potential biomarker of cardiovascular diseases: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:933913. doi:10.3389/fcvm.2022.933913
  5. Fucà G, Guarini V, Antoniotti C, et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403-409. doi:10.1038/s41416-020-0894-7
  6. Yu D, Liu J, Meng C, et al. Pan-immune-inflammation value as a novel prognostic biomarker for digestive system cancers: a meta-analysis. World J Surg Oncol. 2024;22(1):306. doi:10.1186/s12957-024-03595-z
  7. Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. 2013;169(1):62-72. doi:10.1016/j.ijcard.2013.08.078
  8. Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49(15):1642-1648. doi:10.1016/j.jacc.2006.12.042
  9. Pauklin P, Zilmer M, Eha J, et al. Markers of inflammation, oxidative stress, and fibrosis in patients with atrial fibrillation. Oxid Med Cell Longev. 2022;2022:4556671. doi:10.1155/2022/4556671
  10. Zhao X, Huang L, Hu J, et al. The association between systemic inflammation markers and paroxysmal atrial fibrillation. BMC Cardiovasc Disord. 2024;24(1):334. doi:10.1186/s12872-024-04004-9
  11. Hu J, Huang L, Zhao X, et al. Strong positive correlations between the levels of systemic inflammation markers and the occurrence of persistent atrial fibrillation. Int Heart J. 2024;65(6):1004-1011. doi:10.1536/ihj.23-665
  12. Kaplan E, Ekızler FA, Saribaş H, et al. Effectiveness of the Systemic Immune Inflammation Index to predict atrial fibrillation recurrence after cryoablation. Biomark Med. 2023;17(2):101-109. doi:10.2217/bmm-2022-0515
  13. Berezin AE. Predictive value of the Systemic Immune Inflammation Index in recurrence of atrial fibrillation after radiofrequency catheter ablation. World J Cardiol. 2025;17(1):102981. doi:10.4330/wjc.v17.i1.102981
  14. Kus G, Cagirci G, Bayar N, et al. Usefulness of the Systemic Immune-inflammation Index in predicting atrial fibrillation recurrence after direct current cardioversion. Biomark Med. 2022;16(11):847-855. doi:10.2217/bmm-2022-0120
  15. Suehiro H, Kiuchi K, Fukuzawa K, et al. Circulating intermediate monocytes and atrial structural remodeling associated with atrial fibrillation recurrence after catheter ablation. J Cardiovasc Electrophysiol. 2021;32(4):1035-1043. doi:10.1111/jce.14929
  16. Shahid F, Lip GYH, Shantsila E. Role of monocytes in heart failure and atrial fibrillation. J Am Heart Assoc. 2018;7(3):e007849. doi:10.1161/JAHA.117.007849
  17. Li Y, Bai G, Gao Y, et al. The Systemic Immune-inflammatory Response Index can predict the clinical prognosis of patients with initially diagnosed coronary artery disease. J Inflamm Res. 2023;16:5069-5082. doi:10.2147/JIR.S432506
  18. Fu C, Mao Y. Association between pan-immune-inflammation value and heart failure: evidence from the NHANES 2011-2020. J Int Med Res. 2025;53(3):3000605251325176. doi:10.1177/03000605251325176
  19. Muheeb G, Yusuf J, Mehta V, et al. Systemic Immune-inflammatory Response Index (SIIRI) in acute myocardial infarction. Coron Artery Dis. 2025;36(2):139-150. doi:10.1097/MCA.0000000000001454
  20. Gu P, Xu P, Chen Y, et al. The predictive value of pan-immune inflammatory index for early recurrence of atrial fibrillation after cryoablation. BMC Cardiovasc Disord. 2024;24(1):669. doi:10.1186/s12872-024-04329-5
  21. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109-279. doi:10.1016/j.jacc.2023.08.017
  22. Zacharia E, Papageorgiou N, Ioannou A, et al. Inflammatory biomarkers in atrial fibrillation. Curr Med Chem. 2019;26(5):837-854. doi:10.2174/0929867324666170727103357
  23. Zhou X, Dudley Jr SC. Evidence for inflammation as a driver of atrial fibrillation. Front Cardiovasc Med. 2020;7:62. doi:10.3389/fcvm.2020.00062
  24. Boyalla V, Harling L, Snell A, et al. Biomarkers as predictors of recurrence of atrial fibrillation post ablation: an updated and expanded systematic review and meta-analysis. Clin Res Cardiol. 2022;111(6):680-691. doi:10.1007/s00392-021-01978-w
  25. Ozkan E, Elcik D, Barutcu S, et al. Inflammatory markers as predictors of atrial fibrillation recurrence: exploring the C-reactive protein to albumin ratio in cryoablation patients. J Clin Med. 2023;12(19):6313. doi:10.3390/jcm12196313
  26. Peng L, Liu L, Chai M, et al. Predictive value of neutrophil to lymphocyte ratio for clinical outcome in patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1461923. doi:10.3389/fcvm.2024.1461923
  27. Dereli S, Bayramoglu A, Yontar OC. Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion. Ann Noninvasive Electrocardiol. 2019;24(2):e12616. doi:10.1111/anec.12616